-
Product Insights
NewLeber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024
Empower your strategies with our Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties; rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age,...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenadogene Nolparvovec in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenadogene Nolparvovec in Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenadogene Nolparvovec in Leber's Hereditary Optic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GS-030 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GS-030 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GS-030 in Retinitis Pigmentosa (Retinitis) Drug Details: GS-030 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-1092 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-1092 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-1092 in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenadogene Nolparvovec in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lenadogene Nolparvovec in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)Drug Details:lenadogene nolparvovec (GS-010) is under development...
-
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GS-030
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GS-030 Drug Details GS-030 is under development for the treatment of retinitis pigmentosa, geographic...